Pathophysiology of progressive nephropathies

New England Journal of Medicine

Volumn 339, Issue 20, 1998, Pages 1448-1456

  Remuzzi, Giuseppe ^a,b   Bertani, Tullio ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CREATININE URINE LEVEL; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HORMONE ACTION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; PERMEABILITY; PROTEINS; PROTEINURIA;

EID: 0032512094     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199811123392007     Document Type: Review

References (95)

1. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307: 652-9.
2. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev 1979;59:137-64.
3. Johnson HA, Vera Roman JM. Compensatory renal enlargement: hypertrophy versus hyperplasia. Am J Pathol 1966;49:1-13.
4. Anderson S, Meyer TW, Brenner BM. The role of hemodynamic factors in the initiation and progression of renal disease. J Urol 1985;133:363-8.
5. Chanutin A, Ferris EB Jr. Experimental renal insufficiency produced by partial nephrectomy: control diet. Arch Intern Med 1932;49:767-87.
6. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-9.
7. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
8. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
9. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36: 526-36.
10. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996;7:653-60.
11. Bohrer MP, Deen WM, Robertson CR, Brenner BM. Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol 1977;233:F13-F21.
12. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384-94.
13. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986;30:488-96.
14. Bertani T, Zoja C, Abbate M, Rossini M, Remuzzi G. Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. Lab Invest 1989;60:196-204.
15. Eddy AA. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 1989;135:719-33.
16. Park CH, Maack T. Albumin absorption and catabolism by isolated perfused proximal convoluted tubules of the rabbit. J Clin Invest 1984;73: 767-77.
17. Benigni A, Zoja C, Remuzzi G. The renal toxicity of sustained glomerular protein traffic. Lab Invest 1995;73:461-8.
18. Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934-41.
19. Wang Y, Chen J, Chen L, Tay Y-C, Rangan GK, Harris DCH. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997;8:1537-45.
20. Tucker BJ, Rasch R, Blantz RC. Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats. J Clin Invest 1993;92:686-94.
21. Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int 1998;53:1608-15.
22. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-71.
23. Wenzel UO, Abboud HE. Chemokines and renal disease. Am J Kidney Dis 1995;26:982-94.
24. Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354-8.
25. Zoja C, Corna D, Bruzzi I, et al. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Nephrol 1996;4:213-21.
26. Zoja C, Liu X-H, Abbate M, et al. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Exp Nephrol 1998;6:121-31.
27. Hocher B, Thone-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-9.
28. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546-57.
29. Proudfoot AE, Power CA, Hoogewerf AJ, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-603.
30. Lloyd CM, Minto AW, Dorf ME, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997;185:1371-80.
31. Abbate M, Zoja C, Carla D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998;9:1213-24.
32. Pichler R, Giachelli CM, Lombards D, et al. Tubulointerstitial disease in glomerulonephritis: potential role of osteopontin (uropontin). Am J Pathol 1994;144:915-26.
33. Pahl HL, Baeuerle PA. A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-κB. EMBO J 1995;14:2580-8.
34. Barnes PJ, Karin M. Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
35. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995;10:899-909.
36. Rovin BH, Dickerson JA, Tan LC, Hebert CA. Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells. Kidney Int 1995;48:1263-71.
37. Nomura A, Morita Y, Maruyama S, et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol 1997;151:539-47.
38. Biancone L, David S, Della Pietra V, Montrucchio G, Cambi V, Camussi G. Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int 1994;45:451-60.
39. Eddy A. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495-508.
40. Idem. Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. Kidney Int Suppl 1996;54:S-49-S-54.
41. Ong ACM, Jowett TP, Firth JD, Burton S, Kitamura M, Fine LG. A new paracrine loop implicated in human tubulo-interstitial fibrosis: tubular-derived endothelins modulate renal interstitial fibroblast function. J Am Soc Nephrol 1993;4:473. abstract.
42. Strutz F, Okada H, Lo CW, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995;130:393-405.
43. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp 1 in epithelial-mesenchymal transformation. Am J Physiol 1997;273:F563-F574.
44. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN. Angiotensin Il-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 1993;92:1366-72.
45. Wolf G, Killen PD, Neilson EG. Intracellular signaling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Regul 1991;2:219-27.
46. Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464-74.
47. Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996;7:2025-43.
48. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996;49: 578-97.
49. Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993;44:313-21.
50. Yee J, Kuncio GS, Neilson EG. Tubulointerstitial injury following glomerulonephritis. Semin Nephrol 1991;11:361-6.
51. Hirschberg R. Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I. J Clin Invest 1996;98:116-24.
52. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988;82:1757-68.
53. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990;85:541-9.
54. Marinides GN, Groggel GC, Cohen AH, et al. Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy. Am J Pathol 1987;129:394-401.
55. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988;82:322-30.
56. Zoja C, Donadelli R, Corna D, et al. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 1997;29:254-64.
57. Cameron JS, Turner DR, Ogg CS, Chantier C, WUliams DG. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978;10:213-8.
58. Mallick NP, Short CD, Hunt LP. How far since Ellis? The Manchester Study of glomerular disease. Nephron 1987;46:113-24.
59. Wehrmann M, Bohle A, Bogenschutz O, et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis: an analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol 1989;31:67-76.
60. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;2:363-6.
61. Rossing P, Hommel E, Smidt UM, Parving H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993;42:715-9.
62. Mackensen-Haen S, Eissele R, Bohle A. Contribution on the correlation between morphometric parameters gained from the renal cortex and renal function in IgA nephritis. Lab Invest 1988;59:239-44.
63. Schmitt H, Cavalcanti de Oliveira V, Bohle A. Tubulo-interstitial alterations in type I membranoproliferative glomerulonephritis: an investigation of 259 cases. Pathol Res Pract 1987;182:6-10.
64. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991;187:251-9.
65. D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992;20:315-23.
66. Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H. Long-term prognosis of focal sclerosing glomerulonephritis: an analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33:115-22.
67. Nadasdy T, Silva FG, Hogg RJ. Minimal change nephrotic syndrome - focal sclerosis complex (including IgM nephropathy and diffuse mesangial hypercellularity). In: Tisher CG, Brenner BM, eds. Renal pathology. Philadelphia: J.B. Lippincott, 1994:330-89.
68. Schnaper HW, Robson AM. Nephrotic syndrome: minimal change diseases, focal glomerulosclerosis, and related disorders. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. 6th ed. Vol. 2. Boston: Little, Brown, 1997:1725-80.
69. McGovern VJ. Persistent nephrotic syndrome: a renal biopsy study. Australas Ann Med 1964;13:306-12.
70. Hayslett JP, Krassner LS, Bensch KG, Kashgarian M, Epstein FH. Progression of "lipoid nephrosis" to renal insufficiency. N Engl J Med 1969; 281:181-7.
71. Churg J, Habib R, White RHR. Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet 1970;760:1299-302.
72. White RH, Glasgow EF, Mills RJ. Clinicopathological study of nephrotic syndrome in childhood. Lancet 1970;1:1353-9.
73. Habib R, Kleinknecht C. The primary nephrotic syndrome of childhood: classification and clinicopathologic study of 406 cases. Pathol Annu 1971;6:417-74.
74. Siegel NJ, Kashgarian M, Spargo BH, Hayslett JP. Minimal change and focal sclerotic lesions in lipoid nephrosis. Nephron 1974;13:125-37.
75. Cameron JS, Glassock RJ. Natural history and outcome of the nephrotic syndrome. In: Cameron IS, Glassock RJ, eds. The nephrotic syndrome. New York: Marcel Dekker, 1988:999-1033.
76. Rich AR. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 1957;100:173-86.
77. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 1996;50:1651-8.
78. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
79. Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA, Rodicio JL. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990;8:525-31.
80. Mogensen CE, Christensen CK, Beck-Nielsen H. Early changes in kidney function, blood pressure and the stages in diabetic nephropathy. In: Keen H, Legrain M, eds. Prevention and treatment of diabetic nephropathy. Boston: MTP Press, 1983:57-83.
81. Ruggenenti P, Perna A, Mosconi L, et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. Kidney Int Suppl 1997;63:S-54-S-57
82. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543-6.
83. Lemann J Jr, Doumas BT. Proteinuria in health and disease assessed by measuring the urinary protein/creatinine ratio. Clin Chem 1987;33: 297-9.
84. Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. Am J Kidney Dis 1995;26:904-9.
85. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998;316:504-9.
86. Wapstra FH, Navis G, de Jong PE, de Zeeuw D. Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp Nephrol 1996;4:Suppl 1:47-52.
87. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43.
88. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. [Erratum N Engl J Med 1993;330:152.]
89. Breyer JA. Medical management of nephropathy in type I diabetes mellitus: current recommendations. J Am Soc Nephrol 1995;6:1523-9.
90. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
91. Gruppo Italiano Studi Epidemiologici in Nefrologia (G.I.S.E.N.). A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol 1991; 3:193-202.
92. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
93. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995;10:Suppl 9:39-45.
94. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-38.
95. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994;7:84S-92S.